Capstone Triton Financial Group LLC Sells 669 Shares of GSK plc (NYSE:GSK)

Capstone Triton Financial Group LLC cut its position in shares of GSK plc (NYSE:GSK) by 7.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,781 shares of the pharmaceutical company’s stock after selling 669 shares during the quarter. Capstone Triton Financial Group LLC’s holdings in GSK were worth $318,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Eastern Bank purchased a new position in GSK during the third quarter valued at $26,000. Concord Wealth Partners raised its stake in shares of GSK by 231.8% in the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 547 shares during the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in shares of GSK in the second quarter worth $37,000. Fortitude Family Office LLC purchased a new position in shares of GSK in the third quarter worth $42,000. Finally, PrairieView Partners LLC purchased a new position in shares of GSK in the second quarter worth $47,000. 15.74% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

GSK has been the subject of several recent analyst reports. Argus upgraded GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Jefferies Financial Group boosted their target price on GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday, July 2nd. Barclays upgraded GSK to a “hold” rating in a report on Tuesday, August 27th. Finally, UBS Group cut GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Four analysts have rated the stock with a hold rating, two have issued a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $50.00.

GSK Stock Performance

GSK stock traded down $1.30 during midday trading on Wednesday, reaching $36.87. The stock had a trading volume of 4,517,565 shares, compared to its average volume of 3,761,924. The stock has a market cap of $76.41 billion, a PE ratio of 13.83, a P/E/G ratio of 1.23 and a beta of 0.65. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82. The firm has a fifty day simple moving average of $40.98 and a two-hundred day simple moving average of $41.11. GSK plc has a 52-week low of $33.67 and a 52-week high of $45.92.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. The company had revenue of $9.95 billion during the quarter, compared to analyst estimates of $9.49 billion. GSK had a return on equity of 51.48% and a net margin of 12.87%. As a group, equities research analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 10th. Shareholders of record on Friday, August 16th were paid a dividend of $0.3843 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $1.54 dividend on an annualized basis and a dividend yield of 4.17%. This is a positive change from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is presently 55.80%.

Insider Activity

In other news, major shareholder Plc Gsk bought 2,791,930 shares of the business’s stock in a transaction on Friday, September 27th. The shares were bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the transaction, the insider now directly owns 16,775,691 shares in the company, valued at $134,205,528. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 10.00% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.